On ECHEMI
Home > Drugs > Shanghai Haihong Industry (Group) Chaohu Jinchen Pharmaceutical Co., Ltd.
Shanghai Haihong Industry (Group) Chaohu Jinchen Pharmaceutical Co., Ltd.
  • Founded in:

    2002-11-26
  • Country:

    China China
  • Address:

    No. 18, Yicheng Road, Chaohu City, Anhui Province
  • Tax NO.:

    91340181744869155N
  • Registered Funds:

    31 million yuan
  • Website:

  • Email:

Related Drugs
Quick-acting Heartache Pills
Peony bark, Chuanxiong, Borneol
Name Description Content CAS NO. Registered Holders
MOUTAN CORTEX

It can counteract the ST segment elevation of the electrocardiogram after myocardial ischemia in rats induced by coronary artery ligation or intravenous injection of posterior pituitary hormone; prolong the survival time of mice in a normobaric hypoxic environment; and improve the auricle microcirculation disorder of mice induced by intravenous injection of high-molecular-weight dextran.

More

It can counteract the ST segment elevation of the electrocardiogram after myocardial ischemia in rats induced by coronary artery ligation or intravenous injection of posterior pituitary hormone; prolong the survival time of mice in a normobaric hypoxic environment; and improve the auricle microcirculation disorder of mice induced by intravenous injection of high-molecular-weight dextran.

0
Riligustilide

It can counteract the ST segment elevation of the electrocardiogram after myocardial ischemia in rats induced by coronary artery ligation or intravenous injection of posterior pituitary hormone; prolong the survival time of mice in a normobaric hypoxic environment; and improve the auricle microcirculation disorder of mice induced by intravenous injection of high-molecular-weight dextran.

More

It can counteract the ST segment elevation of the electrocardiogram after myocardial ischemia in rats induced by coronary artery ligation or intravenous injection of posterior pituitary hormone; prolong the survival time of mice in a normobaric hypoxic environment; and improve the auricle microcirculation disorder of mice induced by intravenous injection of high-molecular-weight dextran.

89354-45-0 0
Borneol

It can counteract the ST segment elevation of the electrocardiogram after myocardial ischemia in rats induced by coronary artery ligation or intravenous injection of posterior pituitary hormone; prolong the survival time of mice in a normobaric hypoxic environment; and improve the auricle microcirculation disorder of mice induced by intravenous injection of high-molecular-weight dextran.

More

It can counteract the ST segment elevation of the electrocardiogram after myocardial ischemia in rats induced by coronary artery ligation or intravenous injection of posterior pituitary hormone; prolong the survival time of mice in a normobaric hypoxic environment; and improve the auricle microcirculation disorder of mice induced by intravenous injection of high-molecular-weight dextran.

507-70-0 1
Quick-acting Heartache Pills
Borneol, Ligusticum chuanxiong, and Paeonia suffruticosa root bark.
Name Description Content CAS NO. Registered Holders
Borneol

Counteract post-ischemic electrocardiogram ST segment elevation; prolong the survival time of mice in a normobaric hypoxic environment and improve microcirculatory disorders.

More

Counteract post-ischemic electrocardiogram ST segment elevation; prolong the survival time of mice in a normobaric hypoxic environment and improve microcirculatory disorders.

507-70-0 1
Riligustilide

Counteract post-ischemic electrocardiogram ST segment elevation; prolong the survival time of mice in a normobaric hypoxic environment and improve microcirculatory disorders.

More

Counteract post-ischemic electrocardiogram ST segment elevation; prolong the survival time of mice in a normobaric hypoxic environment and improve microcirculatory disorders.

89354-45-0 0
MOUTAN CORTEX

Counteract post-ischemic electrocardiogram ST segment elevation; prolong the survival time of mice in a normobaric hypoxic environment and improve microcirculatory disorders.

More

Counteract post-ischemic electrocardiogram ST segment elevation; prolong the survival time of mice in a normobaric hypoxic environment and improve microcirculatory disorders.

0
Clarithromycin Capsules
Clarithromycin.
Name Description Content CAS NO. Registered Holders
Clarithromycin

This product is a macrolide antibiotic, which has inhibitory effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus peptostreptococcus, and Propionibacterium acnes. In addition, it also has inhibitory effects on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. There is cross-resistance between this product and erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect.

More

This product is a macrolide antibiotic, which has inhibitory effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus peptostreptococcus, and Propionibacterium acnes. In addition, it also has inhibitory effects on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. There is cross-resistance between this product and erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect.

81103-11-9 46
Gentamycin Procaine Vitamin B12 Granules
This product is a compound preparation, with each bag containing 5g of gentamicin sulfate 20mg (20,000 units), procaine hydrochloride 0.1g, and vitamin B12 0.02mg.
Name Description Content CAS NO. Registered Holders
Gentamicin sulfate

It has antibacterial effects on various Gram-negative bacteria, Gram-positive bacteria and Helicobacter pylori. Its mechanism of action is to inhibit the synthesis of bacterial proteins.

More

It has antibacterial effects on various Gram-negative bacteria, Gram-positive bacteria and Helicobacter pylori. Its mechanism of action is to inhibit the synthesis of bacterial proteins.

20mg 1405-41-0 29
Procaine hydrochloride

It has a local anesthetic effect. Its mechanism of action is to competitively bind to the nerve membrane lipoprotein, block sodium ions, and hinder the conduction of nerve fibers.

More

It has a local anesthetic effect. Its mechanism of action is to competitively bind to the nerve membrane lipoprotein, block sodium ions, and hinder the conduction of nerve fibers.

0.1g 51-05-8 11
Vitamin B12

It is a substance necessary for the formation of normal epithelial cells in the digestive tract

More

It is a substance necessary for the formation of normal epithelial cells in the digestive tract

0.02mg 68-19-9 16
Potassium Chloride Sustained Release Tablets
The main ingredient of this product and its chemical name is potassium chloride.
Name Description Content CAS NO. Registered Holders
Potassium chloride

Potassium is the main cation in cells, with a concentration of 150-160 mmol/L; while the main cation outside cells is sodium ion, with a potassium concentration of only 3.5-5 mmol/L. The body mainly relies on Na+-K±ATPase on the cell membrane to maintain the concentration difference between K+ and Na+ in cells. The acid-base balance in the body has an impact on potassium metabolism. For example, when acidosis occurs, H+ enters the cell. In order to maintain the potential difference of the cell, K+ is released outside the cell, causing or aggravating hyperkalemia. Metabolic disorders can also affect acid-base balance. The normal intracellular and extracellular potassium ion concentration and concentration difference are closely related to some important functions of cells, including maintaining carbohydrate metabolism, glycogen storage, protein metabolism, intracellular osmotic pressure and acid-base balance, myocardial excitability and conductivity; maintaining normal skeletal muscle tension and nerve impulse conduction, and increasing the tension of intestinal, uterine and bronchial smooth muscles.

More

Potassium is the main cation in cells, with a concentration of 150-160 mmol/L; while the main cation outside cells is sodium ion, with a potassium concentration of only 3.5-5 mmol/L. The body mainly relies on Na+-K±ATPase on the cell membrane to maintain the concentration difference between K+ and Na+ in cells. The acid-base balance in the body has an impact on potassium metabolism. For example, when acidosis occurs, H+ enters the cell. In order to maintain the potential difference of the cell, K+ is released outside the cell, causing or aggravating hyperkalemia. Metabolic disorders can also affect acid-base balance. The normal intracellular and extracellular potassium ion concentration and concentration difference are closely related to some important functions of cells, including maintaining carbohydrate metabolism, glycogen storage, protein metabolism, intracellular osmotic pressure and acid-base balance, myocardial excitability and conductivity; maintaining normal skeletal muscle tension and nerve impulse conduction, and increasing the tension of intestinal, uterine and bronchial smooth muscles.

7447-40-7 39
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.